HUTCHMED (China) Ltd (HCM): R&D Expense
$148.29M
Year ended 2025-12-31
-27.4%
3-year compound annual growth
-3.2%
5-year compound annual growth
+12.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $148.29M | -30.1% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $212.11M | -29.8% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $302.00M | -21.9% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $386.89M | +29.4% | 2025-03-19, From 2022-01-01 |
| 2021-12-31 | $299.09M | +71.1% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $174.78M | +26.5% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $138.19M | +21.0% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $114.16M | +51.2% | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | $75.52M | +12.9% | 2020-03-03, From 2017-01-01 |
| 2016-12-31 | $66.87M | +41.2% | 2019-03-11, From 2016-01-01 |
| 2015-12-31 | $47.37M | +58.3% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $29.91M | n/a | 2017-03-13, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $148.29M | -30.1% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $44.54M | -11.4% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $186.18M | +32.4% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $451.95M | -10.8% |
| Insmed Inc (INSM) | 2025-12-31 | $771.09M | +28.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $124.03M | +17.9% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $206.01M | -5.3% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $160.22M | +69.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
Compare HCM, ORGO, MIRM, BBIO side by side · Screen every company in Pharmaceutical Preparations ↗